Opportunities and challenges following approval of resmetirom for MASH liver disease
Jeffrey V. Lazarus(The Graduate Center, CUNY), Paul Brennan(University of Dundee), Dana Ivancovsky‐Wajcman(Global Health Council), Christopher J. Kopka, Zobair M. Younossi(Georgetown University), Henry E. Mark(The Geneva Association), Nevin Cohen(The Graduate Center, CUNY), Michael Betel(Digital Research Alliance of Canada), Meena B. Bansal(Mount Sinai Hospital)
Cited by 57
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Annals of Hepatology|2023|789